Blueprint Medicines Liabilities 2025

Blueprint Medicines Aktienanalyse

What does Blueprint Medicines do?

Blueprint Medicines Corp is a biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company was founded in 2008 by a team of experts in the field of molecular biology, biochemistry, and cancer research and is headquartered in Cambridge, Massachusetts, USA. History Blueprint Medicines started as a spin-off from the Broad Institute of MIT and Harvard, a partnership between the Massachusetts Institute of Technology and Harvard University. The founders' goal was to develop a new type of drugs based on the genetic cause of diseases, rather than just treating symptoms. In 2016, the company went public and has since experienced rapid growth. Blueprint Medicines has generated significant revenue through the sale of its products as well as through licensing agreements with other companies. Business model Blueprint Medicines aims to play a leading role in the development of novel drugs based on the identification and treatment of gene mutations. The company utilizes a combination of computer technology, molecular biology, chemistry, and clinical research to specifically target the causes of diseases. Blueprint Medicines has three main areas of focus: 1. Oncology The main focus of Blueprint Medicines is cancer research. The company has several drugs in development that specifically target mutations associated with certain types of cancer. These drugs aim to improve the effectiveness of cancer treatment and enhance patients' quality of life. 2. Blue Flag Technology Blueprint Medicines has developed a proprietary technology called Blue Flag, which allows the company to rapidly and accurately identify and characterize specific mutations in genes. This technology is key to the development of precision medicine approaches tailored to the specific needs of patients. 3. Rare diseases Blueprint Medicines also has a commitment to developing drugs for the treatment of rare diseases. The company collaborates with patients, physicians, and patient organizations to develop drugs that meet the needs of patients with rare diseases. Products Blueprint Medicines has brought several products to market and is working on developing additional products. Here are some of the key products: 1. Ayvakit Ayvakit is a drug for the treatment of gastrointestinal stromal tumors (GIST) associated with a specific genetic mutation. The drug has proven to be highly effective and has been approved by the U.S. Food and Drug Administration (FDA). 2. Gavreto Gavreto is a drug for the treatment of adult patients with a specific genetic mutation associated with non-small cell lung cancer. The drug is being developed in collaboration with pharmaceutical company Roche. 3. Pralsetinib Pralsetinib is a drug for the treatment of patients with a specific gene mutation associated with thyroid cancer. The drug has proven to be highly effective and has been approved by the U.S. FDA. Conclusion Blueprint Medicines Corp is an emerging biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company has established itself as a leader in the field of personalized medicine and has brought several highly effective products to market. Blueprint Medicines continues to work on developing innovative treatment methods for rare diseases and aims to solidify its position as a leading provider of personalized drugs in the global healthcare market. Blueprint Medicines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Blueprint Medicines's Liabilities

Blueprint Medicines's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Blueprint Medicines's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Blueprint Medicines's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Blueprint Medicines's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Blueprint Medicines’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Blueprint Medicines stock

What is the level of liabilities of Blueprint Medicines this year?

Blueprint Medicines has a debt balance of 881.15 M USD this year.

What were the liabilities of Blueprint Medicines compared to the previous year?

The liabilities of Blueprint Medicines have increased by -4.08% dropped compared to the previous year.

What are the consequences of high debt for investors of Blueprint Medicines?

High liabilities can pose a risk for investors of Blueprint Medicines, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Blueprint Medicines?

Low liabilities mean that Blueprint Medicines has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Blueprint Medicines affect the company?

An increase in liabilities of Blueprint Medicines can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Blueprint Medicines affect the company?

A decrease in the liabilities of Blueprint Medicines can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Blueprint Medicines?

Some factors that can influence the liabilities of Blueprint Medicines include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Blueprint Medicines so important for investors?

The liabilities of Blueprint Medicines are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Blueprint Medicines take to modify the liabilities?

To change its liabilities, Blueprint Medicines can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Blueprint Medicines pay?

Over the past 12 months, Blueprint Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Blueprint Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Blueprint Medicines?

The current dividend yield of Blueprint Medicines is .

When does Blueprint Medicines pay dividends?

Blueprint Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Blueprint Medicines?

Blueprint Medicines paid dividends every year for the past 0 years.

What is the dividend of Blueprint Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Blueprint Medicines located?

Blueprint Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Blueprint Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Blueprint Medicines from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.

When did Blueprint Medicines pay the last dividend?

The last dividend was paid out on 9/26/2025.

What was the dividend of Blueprint Medicines in the year 2024?

In the year 2024, Blueprint Medicines distributed 0 USD as dividends.

In which currency does Blueprint Medicines pay out the dividend?

The dividends of Blueprint Medicines are distributed in USD.